1. Introduction {#sec1}
===============

Acute aortic dissection (AAD) has become a treatable disease due to recent advances in new therapeutic approaches for the management of heart and arterial diseases; however, development of quick and economic diagnostic methods remains a challenge. Variability in disease presentation often obscures diagnoses, and imaging modalities such as computed tomography (CT), magnetic resonance imaging (MRI), and esophagus ultrasound remain prohibitive due to cost and availability. Aortic dissection remains a frequent target of medicolegal litigations with accusations of failure to diagnose against treating physicians and hospitals \[[@B1]\]. Some progress in the biochemical diagnosis of AAD has been made in the last decade \[[@B2], [@B3]\]; several acute phase proteins and coagulation parameters were identified to increase in AAD patients, but these are nonspecific biomarkers for AAD as they may be also aberrantly expressed in other disease conditions such as acute myocardial infarction (AMI).

Recently a quantitative proteomic assay, isobaric tags for relative and absolute quantitation (iTRAQ), has been developed and utilized to identify biomarkers for various disease conditions \[[@B4], [@B5]\]. This chemical labeling method involves the stable incorporation of isotopes into an amine tagging reagent, which can then be reliably detected by mass spectrometry, thereby permitting comparative quantitation of various proteins in a multiplex manner. It has been suggested to be suitable for the discovery of biomarkers in a wide range of body fluids and tissues, including serum and plasma \[[@B5], [@B6]\]. With this method, we expect to find the potential biomarkers which are released from the disruption of the aortic media and can provide sufficient specificity and longer time window for the diagnosis of AAD.

2. Materials and Methods {#sec2}
========================

2.1. Samples {#sec2.1}
------------

The study included a total of 30 healthy individuals and 90 patients (60 AAD, 30 AMI). All the patients were selected in a consecutive manner from the period of July 2009 to November 2011 from Fudan University affiliated Zhongshan Hospital (Shanghai, China). iTRAQ analysis was performed for the first twenty patients (10 AAD and 10 AMI) and ten healthy individuals. All patients presented within 72 hours after an episode of chest and/or back pain lasting 5 minutes or more. The diagnosis of AAD was confirmed by computed tomographic arteriography (CTA). The AMI patient was confirmed by electrocardiography (ECG) and cardiac troponin T (cTNT) tests. All patients gave their informed consent for the study. The protocol was approved by the Ethics Committee of Zhongshan Hospital.

For each study subject, whole blood samples were immediately collected in BD Vacutainer SST tubes (BD Diagnostics, Plymouth, UK) after admission and centrifuged at 4000 rpm for 10 min at room temperature. The serum was frozen and stored in aliquots at −80°C until analysis.

2.2. Serum C-Reactive Protein and Myoglobin Test {#sec2.2}
------------------------------------------------

Vitros 5.1 FS automatic biochemistry analyzer (Johnson & Johnson; Calif, USA) was used for serum C-reactive protein (CRP) test, and Cobas e411 immunoassay analyzer (Roche; Mannheim, Germany) was used for the serum myoglobin (Myo) test. The results were then interpreted in accordance with that tested by the International Federation of Clinical Chemistry (IFCC) recommended method. Analyses were performed immediately after the centrifugation of whole blood samples.

2.3. iTRAQ Sample Preparation: Strong Cation Exchange (SCX) Chromatography {#sec2.3}
--------------------------------------------------------------------------

iTRAQ reagents were purchased from Applied Biosystems (Foster City, USA). Fourteen interfering highly abundant proteins from serum samples were removed using Agilent multiple affinity removal liquid chromatography (LC) column-Human 14 (MARS) (shimadzu, Kyoto, Japan). One hundred micrograms of each extract were precipitated using acetone at −20°C and suspended in 20 *μ*L of dissolution buffer (Applied Biosystems, Foster City, USA). After reduction and alkylation, each sample was digested with trypsin (w(trypsin) : w(protein) = 1 : 20) at 37°C overnight. The tryptic peptides were labeled with the iTRAQ reagents as follows: normal controls group was labeled with iTRAQ 113, AMI group was labeled with iTRAQ 114, and AAD group was labeled with iTRAQ 115. The peptides were pooled and desalted with Sep-Pak Vac C18 (Waters, Milford, USA). The peptide mixture was diluted with buffer A containing 10 mM KH~2~PO~4~ in 25% acetonitrile (ACN) at pH 2.6. The peptides were fractionated by 20AD high-performance liquid chromatography (HPLC) system (Shimadzu; Kyoto, Japan) equipped with a polysulfoethyl A column (2.1 mm × 100 mm, 5u, 200 A; The Nest Group, Southborough, Mass). The composition of buffer B was 350 mM KCl, 10 mM KH~2~PO~4~, and 25% ACN at pH 2.6. Separation was performed using a linear binary gradient of 0--80% buffer B in buffer A at a flow rate of 200 *μ*L/min for 60 min. The fractions were combined into 20 groups.

2.4. LC-MS Analysis {#sec2.4}
-------------------

Each SCX fraction was dried down by the rotary vacuum concentrator, dissolved in buffer C (0.1% formic acid, 5% ACN, 95% water), and analyzed on Qstar XL (Applied Biosystems; Foster City, USA). The HPLC gradient was 5--35% buffer D (95% ACN, 0.1% formic acid) in buffer C at a flow rate of 300 nL/min for 70 min. Analysis survey scans were acquired MS from m/z 400--1800 with up to 4 precursors selected for MS/MS from m/z 100--2000.

2.5. The Confirmative ELISA Analysis for Lumican {#sec2.5}
------------------------------------------------

The confirmative ELISA analysis for Lumican was performed using the kits from CUSABIO BIOTECH CO, following manufacture\'s recommendation (CUSABIO BIOTECH CO., LTD., Wuhan, China).

2.6. Data Analysis {#sec2.6}
------------------

All statistical analyses were performed in SPSS 12.0 (SPSS Inc. Chicago, USA). Results were presented as Mean ± SD. A comparative analysis of multiple groups was performed with a one-way-ANOVA or Mann-Whitney/Kruskal-Wallis Test. Statistical significance was defined as *P* \< 0.05. Peptide and protein identification was performed by searching the MS/MS spectra against the SwissProt database using the local Protein Pilot 2.0.1 software. Only peptides identified with confidence interval values of no less than 95% (Unused ProtScore \>1.3) were used for protein identification compilation and subsequent quantitation calculation. Fold changes of \>2 or \<0.5 were set as cut-off values to designate significant differences in protein expression among the AAD group and the normal control group.

2.7. PANTHER Analysis {#sec2.7}
---------------------

The PANTHER database was used to elucidate cellular components, biological processes, and the molecular functions associated with each individual protein (<http://www.pantherdb.org/>).

3. Results {#sec3}
==========

3.1. Clinical Features of Study Subjects {#sec3.1}
----------------------------------------

The clinical features of the AAD patients, AMI patients, and normal controls are summarized in [Table 1](#tab1){ref-type="table"}. There were no differences in age distribution and sex composition among the three groups involved either for ELISA analysis (*N* = 120) (*P* = 0.351 and 0.378, resp.,) or iTRAQ analysis (*P* = 0.241 and 0.873, resp.). There was no differences in the time from onset to admission between AAD and AMI group either (*P* = 0.776).

3.2. Functional Classification of Identified Proteins by iTRAQ {#sec3.2}
--------------------------------------------------------------

A total of 174 proteins with confidence interval values of no less than 95% were identified (Unused ProtScore \> 1.3). However, after manually rechecking the MS/MS data thoroughly peak by peak, 155 proteins (89.08%) had a relative quantitation of one or more peptides. Fifteen proteins had no quantifiable peptides that could be ascertained, and four proteins had peptides with confidence interval values that were less than 95%.

In total, 174 proteins were sorted using the PANTHER classification system, which sorts the proteins into respective categories based on their molecular functions. The major groups include: signaling molecules (13%), enzyme modulators (12%), transfer/carrier proteins (11%), and proteases (10%). Other groups include: structural proteins (1%), cell adhesion molecules (1%), cytoskeletal proteins (3%), extracellular matrix proteins (2%), and cell junction proteins (1%).

As a way to cross-check the reliability of quantitation of iTRAQ reagent, serum CRP and Myo levels were assessed using both conventional biochemical and immunoassay tests and iTRAQ analysis on the same specimens. With biochemical and immunoassay analysis, CRP was 41.31 ± 32.76 mg/mL and Myo was 66.42 ± 81.23 mg/mL in AAD group, while in normal controls, the former was 5.88 ± 1.42 and the latter was 32.07 ± 14.14 mg/mL. CRP and Myo levels of AAD patients were 7.03-fold and 2.07-fold higher, respectively, than normal controls. Using iTRAQ, the AAD/normal controls ratios of CRP and Myo were similar at 9.12-fold ([Table 2](#tab2){ref-type="table"}) and 1.47-fold. The ratios of CRP and Myo among three groups were similar with either biochemical and immunoassay or iTRAQ analysis, confirming the reliability of iTRAQ analysis.

3.3. Proteins with Over Twofold Differential Expression {#sec3.3}
-------------------------------------------------------

A total of 155 proteins had a relative quantitation difference for AAD patients compared with the normal control group of which 46 proteins increased more than twofold ([Table 2](#tab2){ref-type="table"}), while 36 proteins decreased more than twofold among the AAD patients ([Table 3](#tab3){ref-type="table"}). Among the identified proteins with increased levels in AAD, there were a number of acute phase reactants (CRP, Beta-2-microglobulin, Complement factor I), blood coagulation marker (Haptoglobin, Coagulation factor V, Coagulation factor IX), and cellular components (Lumican, Tubulin beta-3 chain, Fibronectin). However when compared to AMI patients, 14 of the 46 protein showed less than 2-fold increase, including complement component 9, complement factor1, Plasma protein C1 inhibitor, and Ig Kappa chain C-region ([Table 2](#tab2){ref-type="table"}). Interestingly, some acute phase proteins such as CRP remains on the list as it showed the differential expression between the two conditions.

Among proteins with decreased expression in AAD patients compared with normal controls, there were a number of molecules involved in protein metabolism (Inter-alpha-trypsin inhibitor heavy chain H2, Alpha-2-HS-glycoprotein), lipid metabolic process (Apolipoprotein A-IV, Apolipoprotein E, Apolipoprotein C-I), blood coagulation marker (Fibrinogen alpha chain, Prothrombin), and cellular components (Alpha-2-HS-glycoprotein, thrombospondin-1 (TSP-1)). When compared to AMI patients, 8 of 36 proteins did not reach the 2-fold differential expression ([Table 3](#tab3){ref-type="table"}).

3.4. The ELISA Analysis of Serum Concentrations of Lumican {#sec3.4}
----------------------------------------------------------

Based on the iTRAQ findings above we selected two targets, Fibronectin and Lumican, the protein markers potentially associated with vascular injury, for the validation using ELISA method. At the initial analysis using 10 AAD and 10 normal samples we found that statistical significant difference between AAD and normal individual was seen for Lumican but not Fibronectin (data not shown). Therefore, we carried a full validation study only for Lumican, using the entire 120 samples collected (see [Table 1](#tab1){ref-type="table"}). A statistical significant difference between AAD, AMI, and normal individual was seen in serum concentrations of Lumican (2.66 ± 4.58 ng/mL in AAD group, 0.69 ± 0.34 ng/mL in AMI group, and 0.85 ± 0.53 ng/mL in normal control, *P* = 0.003). The difference for AAD and AMI also reached statistical significance (*P* \< 0.05) suggesting the specificity of this marker for AAD ([Figure 1](#fig1){ref-type="fig"}). We further analyzed the correlation between Lumican levels with time from onset of symptoms to admission. As shown in [Figure 2](#fig2){ref-type="fig"}, a correlation was seen in AAD group (*r* = 0.256, *P* = 0.048) but not in AMI group (*r* = 0.077, *P* = 0.685), further confirming the specificity of Lumican as a marker for AAD.

4. Discussion {#sec4}
=============

iTRAQ analysis is recently been used as a potentially more effective biomarker discovery method than traditional proteomic methods. The high reproducibility optimizes this technique for embarking on "fishing-expeditions" as an initial screening for potential useful biomarkers \[[@B6]--[@B8]\]. As a means of internal validation, the iTRAQ method was compared with CRP biochemical assay and Myo immunoassay. In our study there were no significant differences in the serum levels determined by the different methods. Thus, the iTRAQ method we employed appears in this preliminary analysis to be suitable for the detection of relevant proteins.

To identify differentially expressed proteins, in many studies, the cut-off points were set at 20% to 50% average variance \[[@B7], [@B9], [@B10]\]. However, such approaches may result in finding markers with low specificity \[[@B2], [@B3]\]. We therefore appropriated to increase the cut-off point at 100% variance in serum levels of candidate proteins between AAD patients and normal subjects. Thus, only twofold changes below or above normal controls were considered significant. In our study, total of 155 proteins had a relative difference between AAD patients and healthy volunteers. Therefore, with higher specificity, these candidate proteins are more likely to be potential biomarkers for AAD.

In the group of significantly increased proteins, there were numerous acute phase reactants, such as Beta-2-microglobulin (P61769), which could be indicative of an increased inflammatory response among AAD patients. CRP (P02741), a protein found to be elevated in patients who presented with symptoms or rupture of AAD and abdominal aortic aneurysm, was also identified using iTRAQ \[[@B11], [@B12]\]. CRP is a nonspecific biomarker associated with AAD and a predictor for long-term adverse events \[[@B13]\], and it can be used to monitor evolution of false lumen thrombosis \[[@B14]\]. Unfortunately, CRP is also produced in coronary plaques \[[@B15]\], acute myocardial infarction \[[@B16]\], and so forth. The elevations of these acute phase reactants represent a generalized reaction to vascular injury, and as such, they are nonspecific biomarkers. In addition, many proteins identified are associated with blood coagulation and fibrinolytic system. Among which, ten had increased serum levels (e.g., P00450-Ceruloplasmin, P02751-Fibronectin, P00738-Haptoglobin...), and twelve had decreased serum levels (e.g., P02671-Fibrinogen alpha chain, P00751-Complement factor B, P00734-Prothrombin...). The pathophysiological mechanism for the appearance of these proteins may be explained by the release of tissue factors from the dissected aortic wall then the activation of the extrinsic coagulation system \[[@B17]--[@B19]\]. In addition, platelets can be activated by injuries to the vessel wall, activation of the coagulation cascade, or by activating factors released from stimulated endothelial cells and platelets (e.g., ADP, thromboxane, von Willebrand Factor). It also has been found that platelet functions were affected secondary to acute massive consumption coagulopathy in the false lumen in AAD patient \[[@B20], [@B21]\].

In the past few years, extracellular matrix (ECM) components of vessel walls such as elastin have been shown to be elevated in aortic dissections; however, such increases were less than twofold \[[@B3]\]. Our study found 9 extracellular matrix component proteins with greater than twofold differences, among these are Carboxypeptidase (P22792), Lumican (P51884), Fibronectin (P02751), Ceruloplasmin (P00450), and Thrombospondin-1 (TSP-1, P07996). Fibronectin is a polymorphic and multifunctional glycoprotein that plays wide-ranging roles in tissue injury \[[@B22]--[@B25]\]. TSP-1, which is an extracellular protein that participates in cell-to-cell and cell-to-matrix communication, can stimulate or inhibit the migration of vascular smooth muscle cells or endothelial cells. It has been known as a plasma marker of peripheral arterial disease \[[@B26]\].

Lumican is distributed in interstitial collagenous matrices throughout the body. In coronary arteries ischemic lesion, it is overexpressed by vascular smooth muscle cells (VSMCs) \[[@B27]\] and also synthesized in aortic smooth muscle cells \[[@B28]\]. In iTRAQ analysis, serum Lumican levels in patients with AAD were 1.29-fold and 3.63-fold higher than in patients with AMI and normal controls, respectively. It is interesting to note that with iTRAQ analysis, the level of difference between AAD and AMI for Lumican is less than that of Fibronectin ([Table 2](#tab2){ref-type="table"}), yet the initial validation using ELISA method showed that only Lumican was significantly increased in AAD and AMI samples. While there may be variety reasons to explain the variations of the findings between the two methods, it highlights the importance of validation in biomarker studies. The finding that Lumican expression correlated with the time from onset to admission only in AAD but not in AMI sample further confirmed the specificity of this protein in association with AAD.

Proteomic approach provides an exciting platform to identify clinically useful protein biomarkers. As an initial step our study identified potential candidate protein biomarkers in the serum of AAD patients with the iTRAQ technique. However, the ultimate development of biomarkers which provide sufficient sensitivity or specificity for the diagnosis of AAD will require multiple validations and clinical testing, which may include nonprotein markers. Nevertheless our findings provide preliminary list of candidate biomarkers that should be further validated, either alone or in combination.

5. Conclusion {#sec5}
=============

In this paper, we found that iTRAQ technique is a suitable approach for the detection of the new potential protein markers in the serum of AAD patients. Using iTRAQ approach, our study identified that Lumican may be a potentially interesting new serum marker of AAD, and upon further validation this marker may assist the clinical diagnosis of AAD.
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###### 

Clinical characteristics in three groups.

                                                              AAD             AMI             Normal controls   *P* value
  ----------------------------------------- ----------------- --------------- --------------- ----------------- -----------
  ELISA test (*N* = 120)                    Age (Mean ± SD)   55.63 ± 16.39   59.70 ± 13.98   59.50 ± 12.65     0.351^a^
  Gender, *n* (%), male                     30 (50)           17 (56.67)      16 (53.33)      0.378^b^          
  Admission after onset hours (Mean ± SD)   20.19 ± 18.09     19.33 ± 15.31   /               0.776^c^          
  Type A *n* (%)                            31 (51.67)        /               /                                 
  Type B *n* (%)                            29 (48.33)        /               /                                 
  Marfan *n* (%)                            7 (11.67)         /               /                                 
                                                                                                                
                                            *n*               10              10              10                
                                                                                                                
  iTRAQ test (*N* = 30)                     Age (Mean ± SD)   51.60 ± 13.22   61.00 ± 5.25    49.9 ± 15.02      0.241^a^
  Gender, *n* (%), male                     6 (60)            6 (60)          5 (50)          0.873^b^          
  Admission after onset hours (Mean ± SD)   27.20 ± 24.56     18.40 ± 23.12   /               0.363^c^          
  Type A *n* (%)                            5 (50)            /               /                                 
  Type B *n* (%)                            5 (50)            /               /                                 
  Marfan *n* (%)                            2 (20)            /               /                                 

^a^ One-way-ANOVA; ^b^Chi-square Test; ^c^Mann-Whitney Test.

###### 

List of the increased (\>2-fold) protein targets identified and their corresponding class, associated biological process, and cellular component.

  N    Unused^a^   Peptides^b^   Accession \#   Name                                                                   Biological process                 Cellular component       Protein class                                     AAD/CON ratio   AAD/AMI ratio
  ---- ----------- ------------- -------------- ---------------------------------------------------------------------- ---------------------------------- ------------------------ ------------------------------------------------- --------------- ---------------
  1    2.7         1             Q13509         Tubulin beta-3 chain                                                   Cellular component morphogenesis   Cytoskelelton            Cytoskeletal protein/tubulin                      39.8406         0.0711
  2    2           1             P01600         Ig kappa chain V-I region Hau                                                                                                      Unclassified                                      31.3480         3.0760
  3    6.67        3             P02743         Serum amyloid P-component                                              Response to stress                                          Defense/immunity protein/antibacterial response   24.4499         9.1241
  4    13.53       10            P05546         Heparin cofactor 2                                                     Protein metabolic process                                   Enzyme modulator                                  19.7628         11.2740
  5    17.67       9             P36955         Pigment epithelium-derived factor                                      Protein metabolic process                                   Enzyme modulator                                  19.7628         9.8135
  6    6.24        4             P05543         Thyroxine-binding globulin                                             Protein metabolic process                                   Enzyme modulator                                  12.7065         3.7665
  7    12.63       18            P01834         Ig kappa chain C region                                                Response to stimulus               Immunoglobulin complex   Defense/immunity protein                          11.6959         1.8031
  8    55.14       43            P02751         Fibronectin                                                            Blood coagulation                  Extracellular matrix     Transfer/carrier protein                          11.5875         3.7327
  9    35.94       29            P01011         Alpha-1-antichymotrypsin                                               Protein metabolic process                                   Enzyme modulator                                  10.5708         8.0906
  10   2.22        1             P02741         C-reactive protein                                                     Response to stress                                          Defense/immunity protein                          9.1241          5.9701
  11   2           1             Q9UK55         Protein Z-dependent protease inhibitor                                 Protein metabolic process                                   Enzyme modulator                                  8.7873          2.4888
  12   100.78      51            P04114         Apolipoprotein B-100                                                   Lipid metabolic process                                     Transfer/carrier protein                          8.6281          2.8050
  13   9.19        4             P35858         Insulin-like growth factor-binding protein complex acid labile chain   Cell-cell adhesion                 Extracellular matrix     Receptor                                          8.4746          4.0177
  14   47.88       42            P19827         Inter-alpha-trypsin inhibitor heavy chain H1                           Protein metabolic process                                   Enzyme modulator                                  5.8072          5.6497
  15   106.72      89            P00450         Ceruloplasmin                                                          Blood coagulation                  Extracellular matrix     Transporter                                       5.1046          9.6339
  16   37.56       23            P04196         Histidine-rich glycoprotein                                            Blood coagulation                                           Unclassified                                      4.6125          3.2206
  17   4.15        2             P08571         Monocyte differentiation antigen CD14                                  Immune system process                                       Receptor                                          4.0933          2.4888
  18   2.72        1             Q96KN2         Beta-Ala-His dipeptidase                                               Protein metabolic process                                   Protease                                          4.0933          1.9231
  19   31.66       20            P01871         Ig mu chain C region                                                   Response to stimulus                                        Defense/immunity protein                          3.8023          2.3552
  20   12.12       6             P51884         Lumican                                                                Cell-cell adhesion                 Extracellular matrix     Receptor                                          3.6311          1.2942
  21   2.71        1             P00740         Coagulation factor IX                                                  Blood coagulation                                           Protease                                          3.4037          2.0137
  22   6.27        3             P08185         Corticosteroid-binding globulin                                        Protein metabolic process                                   Enzyme modulator                                  3.2808          5.4945
  23   2.58        21            P00739         Haptoglobin-related protein                                                                                                        Unclassified                                      3.2206          1.7538
  24   4.98        4             P04003         C4b-binding protein alpha chain                                        Blood coagulation                                           Transfer/carrier protein                          3.1626          5.0582
  25   6.02        6             P02745         Complement C1q subcomponent subunit A                                  Response to stimulus                                        Transfer/carrier protein                          3.1046          3.6982
  26   5.83        3             P22792         Carboxypeptidase N subunit 2                                           Cell adhesion                      Extracellular matrix     Receptor                                          3.0202          1.3805
  27   15.99       11            P05155         Plasma protease C1 inhibitor                                           Protein metabolic process                                   Enzyme modulator                                  2.9647          1.2824
  28   2.02        2             P01742         Ig heavy chain V-I region EU                                                                                                       Unclassified                                      2.8580          1.1695
  29   2           1             P09486         SPARC                                                                  Cell-cell signaling                                         Transfer/carrier protein                          2.7042          0.7312
  30   18.06       9             P02760         Protein AMBP                                                           Blood coagulation                                           Enzyme modulator                                  2.6062          3.5651
  31   8.99        5             P12259         Coagulation factor V                                                   Blood coagulation                  Extracellular matrix     Transporter                                       2.6062          3.2206
  32   8.31        6             P27169         Serum paraoxonase/arylesterase 1                                       Immune system process                                       Oxidoreductase                                    2.5349          5.6497
  33   2.32        1             P19320         Vascular cell adhesion protein 1                                       Cell-cell adhesion                                          Defense/immunity protein                          2.3121          2.1478
  34   2.01        1             O00187         Mannan-binding lectin serine protease 2                                Response to stimulus                                        Protease                                          2.3121          1.5277
  35   43.19       29            P02749         Beta-2-glycoprotein 1                                                  Blood coagulation                                           Transfer/carrier protein                          2.2287          7.1124
  36   3.52        2             P11226         Mannose-binding protein C                                              Response to stimulus                                        Defense/immunity protein                          2.2080          2.6062
  37   87.93       67            P00738         Haptoglobin                                                            Blood coagulation                                           Protease                                          2.1678          3.5651
  38   5.7         4             Q13790         Apolipoprotein F                                                       Lipid metabolic process                                     Transporter                                       2.1478          3.9448
  39   65.42       41            P02790         Hemopexin                                                              Vitamin transport                                           Transfer/carrier protein                          2.1478          3.9078
  40   2.96        1             P20851         C4b-binding protein beta chain                                         Blood coagulation                                           Transfer/carrier protein                          2.1281          4.8309
  41   2           1             P61769         Beta-2-microglobulin                                                   Response to stimulus                                        Defense/immunity protein                          2.1088          2.1281
  42   20.86       10            P02748         Complement component C9                                                Response to stimulus                                        Receptor                                          2.1088          0.6252
  43   6.96        3             P07477         Trypsin-1                                                              Protein metabolic process                                   Protease                                          2.1088          0.3436
  44   13.64       7             P05156         Complement factor I                                                    Response to stimulus                                        Protease                                          2.0325          0.9120
  45   15.17       10            P01842         Ig lambda chain C regions                                              Response to stimulus               Immunoglobulin complex   Defense/immunity protein                          2.0137          2.1678
  46   4.29        1             P35030         Trypsin-3                                                              Protein metabolic process                                   Protease                                          2.0137          1.3931

^a^ Unused \> 1.3 means at least 95% confidence; ^b^number of peptides with 95% confidence; AAD: acute aortic dissection; AMI: acute myocardial infarction; CON: normal controls.

###### 

List of the decreased (\<0.5 folds) protein targets identified and their corresponding class, associated biological process, and cellular component.

  N    Unused^a^   Peptides^b^   Accession \#   Name                                           Biological process                 Cellular component     Protein classification         AAD/CON ratio   AAD/AMI ratio
  ---- ----------- ------------- -------------- ---------------------------------------------- ---------------------------------- ---------------------- ------------------------------ --------------- ---------------
  1    19.31       17            P02775         Platelet basic protein                         Blood coagulation                                         Transfer/carrier protein       0.0209          0.0398
  2    44.6        31            P02671         Fibrinogen alpha chain                         Blood coagulation                  Extracellular matrix   Transfer/carrier protein       0.0370          0.0203
  3    19.82       30            P02656         Apolipoprotein C-III                           Lipid metabolic process                                   Transporter                    0.0570          0.0240
  4    5.7         5             P01717         Ig lambda chain V-IV region Hil                                                                          Unclassified                   0.0655          0.0679
  5    8.45        4             P02768         Serum albumin                                  Transport                                                 Transfer/carrier protein       0.0724          0.8472
  6    3.22        1             P04264         Keratin, type II cytoskeletal 1                Cellular component morphogenesis   Cytoskelelton          Structural protein             0.0780          0.9639
  7    2.05        1             P04070         Vitamin K-dependent protein C                  Blood coagulation                                         Protease                       0.0794          0.0441
  8    34.98       27            P02652         Apolipoprotein A-II                            Lipid metabolic process                                   Transporter                    0.0991          0.1067
  9    20.3        10            P02654         Apolipoprotein C-I                             Lipid metabolic process                                   Transporter                    0.1159          0.0847
  10   94.94       108           P02765         Alpha-2-HS-glycoprotein                        Protein metabolic process          Extracellular matrix   Extracellular matrix protein   0.1180          0.1472
  11   39.07       25            P01008         Antithrombin-III                               Protein metabolic process                                 Enzyme modulator               0.1202          0.0973
  12   72.69       57            P00734         Prothrombin                                    Blood coagulation                                         Enzyme modulator               0.1225          0.2051
  13   6.88        3             P27918         Properdin                                      Response to stimulus                                      Unclassified                   0.1419          0.1905
  14   6.31        4             P69905         Hemoglobin subunit alpha                       Blood circulation                                         Transfer/carrier protein       0.1500          0.2312
  15   8.97        15            Q03591         Complement factor H-related protein 1          Blood coagulation                                         Transfer/carrier protein       0.1706          0.0991
  16   27.03       22            P10909         Clusterin                                      Apoptosis                                                 Unclassified                   0.1905          0.1076
  17   2           1             Q15942         Zyxin                                          Cellular component morphogenesis                          Enzyme modulator               0.1923          0.2109
  18   20.4        26            P01024         Complement C3                                  Protein metabolic process                                 Transfer/carrier protein       0.2070          0.1406
  19   7.43        3             P17936         Insulin-like growth factor-binding protein 3   Cell-matrix adhesion                                      Unclassified                   0.2089          0.3162
  20   2.23        2             P55290         Cadherin-13                                    Cell-cell adhesion                 Cell junction          Receptor                       0.2188          0.1660
  21   1.41        1             P13598         Intercellular adhesion molecule 2              Cell-cell adhesion                                        Transfer/carrier protein       0.2355          0.1600
  22   96.24       64            P00751         Complement factor B                            Blood coagulation                                         Transfer/carrier protein       0.2466          0.2729
  23   28.82       16            P09871         Complement C1s subcomponent                    Blood coagulation                                         Protease                       0.2606          0.4169
  24   13.74       9             P01019         Angiotensinogen                                Protein metabolic process                                 Enzyme modulator               0.2630          0.5058
  25   95.34       74            P19823         Inter-alpha-trypsin inhibitor heavy chain H2   Protein metabolic process                                 Enzyme modulator               0.2805          0.5649
  26   5.15        2             P18065         Insulin-like growth factor-binding protein 2   Cell-matrix adhesion                                      Unclassified                   0.2884          0.3281
  27   16.84       10            P07996         Thrombospondin-1                               Blood coagulation                  Extracellular matrix   Transfer/carrier protein       0.3404          0.8317
  28   5.31        3             P26927         Hepatocyte growth factor-like protein          Blood coagulation                                         Transfer/carrier protein       0.3436          0.3436
  29   7.85        4             O14791         Apolipoprotein L1                              Lipid metabolic process                                   Transporter                    0.3908          0.2831
  30   94.76       57            P06727         Apolipoprotein A-IV                            Lipid metabolic process                                   Transporter                    0.4018          0.1837
  31   14.1        9             P35527         Keratin, type I cytoskeletal 9                 Cellular component morphogenesis                          Structural protein             0.4055          0.7244
  32   9.48        6             P00746         Complement factor D                            Blood coagulation                                         Protease                       0.4571          0.6668
  33   48.09       24            P02649         Apolipoprotein E                               Lipid metabolic process                                   Transporter                    0.4656          0.2051
  34   38.8        32            P02735         Serum amyloid A protein                        Immune system process                                     Transporter                    0.4742          0.0319
  35   9.46        5             P10720         Platelet factor 4 variant                      Blood coagulation                                         Transfer/carrier protein       0.4742          0.5105
  36   53.31       29            P02774         Vitamin D-binding protein                      Transport                                                 Transfer/carrier protein       0.4831          2.2287

^a^ Unused \> 1.3 means at least 95% confidence; ^b^number of peptides with 95% confidence; AAD: acute aortic dissection; AMI: acute myocardial infarction; CON: normal control.

[^1]: Academic Editor: Saulius Butenas
